Long term IL-17A inhibition by secukinumab leads to reduced spinal inflammation and unchanged fatty lesions in patients with ankylosing spondylitis
| Principais autores: | , , , , , , , , , , , , , , , , , |
|---|---|
| Formato: | Journal article |
| Publicado em: |
2013
|
| _version_ | 1826276172767428608 |
|---|---|
| author | Baraliakos, X Braun, J Laurent, D Baeten, D van der Heijde, D Sieper, J Emery, P McInnes, I van Laar, J Landewe, R Wordsworth, P Wollenhaupt, J Kellner, H Wright, A Vandenhende, F Radford, K Borah, B Hueber, W |
| author_facet | Baraliakos, X Braun, J Laurent, D Baeten, D van der Heijde, D Sieper, J Emery, P McInnes, I van Laar, J Landewe, R Wordsworth, P Wollenhaupt, J Kellner, H Wright, A Vandenhende, F Radford, K Borah, B Hueber, W |
| author_sort | Baraliakos, X |
| collection | OXFORD |
| description | |
| first_indexed | 2024-03-06T23:10:01Z |
| format | Journal article |
| id | oxford-uuid:6520c8ca-a5b6-4a67-84db-4c84b6b05c76 |
| institution | University of Oxford |
| last_indexed | 2024-03-06T23:10:01Z |
| publishDate | 2013 |
| record_format | dspace |
| spelling | oxford-uuid:6520c8ca-a5b6-4a67-84db-4c84b6b05c762022-03-26T18:23:38ZLong term IL-17A inhibition by secukinumab leads to reduced spinal inflammation and unchanged fatty lesions in patients with ankylosing spondylitisJournal articlehttp://purl.org/coar/resource_type/c_dcae04bcuuid:6520c8ca-a5b6-4a67-84db-4c84b6b05c76Symplectic Elements at Oxford2013Baraliakos, XBraun, JLaurent, DBaeten, Dvan der Heijde, DSieper, JEmery, PMcInnes, Ivan Laar, JLandewe, RWordsworth, PWollenhaupt, JKellner, HWright, AVandenhende, FRadford, KBorah, BHueber, W |
| spellingShingle | Baraliakos, X Braun, J Laurent, D Baeten, D van der Heijde, D Sieper, J Emery, P McInnes, I van Laar, J Landewe, R Wordsworth, P Wollenhaupt, J Kellner, H Wright, A Vandenhende, F Radford, K Borah, B Hueber, W Long term IL-17A inhibition by secukinumab leads to reduced spinal inflammation and unchanged fatty lesions in patients with ankylosing spondylitis |
| title | Long term IL-17A inhibition by secukinumab leads to reduced spinal inflammation and unchanged fatty lesions in patients with ankylosing spondylitis |
| title_full | Long term IL-17A inhibition by secukinumab leads to reduced spinal inflammation and unchanged fatty lesions in patients with ankylosing spondylitis |
| title_fullStr | Long term IL-17A inhibition by secukinumab leads to reduced spinal inflammation and unchanged fatty lesions in patients with ankylosing spondylitis |
| title_full_unstemmed | Long term IL-17A inhibition by secukinumab leads to reduced spinal inflammation and unchanged fatty lesions in patients with ankylosing spondylitis |
| title_short | Long term IL-17A inhibition by secukinumab leads to reduced spinal inflammation and unchanged fatty lesions in patients with ankylosing spondylitis |
| title_sort | long term il 17a inhibition by secukinumab leads to reduced spinal inflammation and unchanged fatty lesions in patients with ankylosing spondylitis |
| work_keys_str_mv | AT baraliakosx longtermil17ainhibitionbysecukinumableadstoreducedspinalinflammationandunchangedfattylesionsinpatientswithankylosingspondylitis AT braunj longtermil17ainhibitionbysecukinumableadstoreducedspinalinflammationandunchangedfattylesionsinpatientswithankylosingspondylitis AT laurentd longtermil17ainhibitionbysecukinumableadstoreducedspinalinflammationandunchangedfattylesionsinpatientswithankylosingspondylitis AT baetend longtermil17ainhibitionbysecukinumableadstoreducedspinalinflammationandunchangedfattylesionsinpatientswithankylosingspondylitis AT vanderheijded longtermil17ainhibitionbysecukinumableadstoreducedspinalinflammationandunchangedfattylesionsinpatientswithankylosingspondylitis AT sieperj longtermil17ainhibitionbysecukinumableadstoreducedspinalinflammationandunchangedfattylesionsinpatientswithankylosingspondylitis AT emeryp longtermil17ainhibitionbysecukinumableadstoreducedspinalinflammationandunchangedfattylesionsinpatientswithankylosingspondylitis AT mcinnesi longtermil17ainhibitionbysecukinumableadstoreducedspinalinflammationandunchangedfattylesionsinpatientswithankylosingspondylitis AT vanlaarj longtermil17ainhibitionbysecukinumableadstoreducedspinalinflammationandunchangedfattylesionsinpatientswithankylosingspondylitis AT landewer longtermil17ainhibitionbysecukinumableadstoreducedspinalinflammationandunchangedfattylesionsinpatientswithankylosingspondylitis AT wordsworthp longtermil17ainhibitionbysecukinumableadstoreducedspinalinflammationandunchangedfattylesionsinpatientswithankylosingspondylitis AT wollenhauptj longtermil17ainhibitionbysecukinumableadstoreducedspinalinflammationandunchangedfattylesionsinpatientswithankylosingspondylitis AT kellnerh longtermil17ainhibitionbysecukinumableadstoreducedspinalinflammationandunchangedfattylesionsinpatientswithankylosingspondylitis AT wrighta longtermil17ainhibitionbysecukinumableadstoreducedspinalinflammationandunchangedfattylesionsinpatientswithankylosingspondylitis AT vandenhendef longtermil17ainhibitionbysecukinumableadstoreducedspinalinflammationandunchangedfattylesionsinpatientswithankylosingspondylitis AT radfordk longtermil17ainhibitionbysecukinumableadstoreducedspinalinflammationandunchangedfattylesionsinpatientswithankylosingspondylitis AT borahb longtermil17ainhibitionbysecukinumableadstoreducedspinalinflammationandunchangedfattylesionsinpatientswithankylosingspondylitis AT hueberw longtermil17ainhibitionbysecukinumableadstoreducedspinalinflammationandunchangedfattylesionsinpatientswithankylosingspondylitis |